Heart Test Laboratories Secures Foundational Patent for AI-ECG

Heart Test Laboratories, Inc. ( (HSCS) ) has provided an update.

On June 3, 2025, HeartSciences Inc. announced that it was granted a foundational patent by the United States Patent and Trademark Office for estimating echocardiography parameters indicative of heart function using an ECG. This patent further strengthens HeartSciences’ extensive intellectual property portfolio, which includes 44 granted patents across the US and key international markets. The new patent underscores the company’s position as a significant player in the AI-ECG field, potentially enhancing its market positioning and offering considerable value to stakeholders.

The most recent analyst rating on (HSCS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.

Spark’s Take on HSCS Stock

According to Spark, TipRanks’ AI Analyst, HSCS is a Neutral.

The overall score is primarily impacted by the company’s weak financial performance and challenging valuation, indicating significant financial instability. Technical analysis provides some positive signals but is not sufficient to offset the financial concerns.

To see Spark’s full report on HSCS stock, click here.

More about Heart Test Laboratories, Inc.

HeartSciences Inc. is a medical technology company that leverages artificial intelligence to enhance the clinical utility of ECGs (also known as EKGs). The company aims to improve cardiac screening tools, particularly in frontline or point-of-care settings, by providing AI-ECG algorithms on a cloud-based solution and a low-cost ECG hardware platform. HeartSciences’ first product candidate, the MyoVista® wavECG™, is designed to offer diagnostic information related to cardiac dysfunction traditionally available only through cardiac imaging.

Average Trading Volume: 16,027

Technical Sentiment Signal: Sell

Current Market Cap: $3.99M

See more data about HSCS stock on TipRanks’ Stock Analysis page.